Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists.
GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
['AlSheyyab|Rawda Y|RY|', 'Al-Taani|Bashar M|BM|', 'Obeidat|Rana M|RM|', 'Alsmadi|Motasem M|MM|', 'Masaedeh|Rafeef K|RK|', 'Sabat|Raghda N|RN|']
D000818:Animals D004304:Dosage Forms D004333:Drug Administration Routes D007987:Gonadotropin-Releasing Hormone D006727:Hormone Antagonists D006801:Humans
peptide subcutaneous Cetrorelix GnHR antagonist extrusion microparticles testesteron.